

### History of Changes for Study: NCT00794417

## A Study of Afibercept Administered in Combination With Pemetrexed and Cisplatin in Pa Carcinoma

[Latest version \(submitted November 13, 2020\) on ClinicalTrials.gov](#)

- A study version is represented by a row in the table.
- Select two study versions to compare. One each from columns A and B.
- Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The s applies to the Protocol section of the study.
- Click "Compare" to do the comparison and show the differences.
- Select a version's Submitted Date link to see a rendering of the study for that version.
- The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study v
- Hover over the "Recruitment Status" to see how the study's recruitment status changed.
- Study edits or deletions are displayed in red.
- Study additions are displayed in green.

Mylan  
IPF  
U.S.  
E

### Study Record Versions

Version	A	B	Submitted Date	Changes
1	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<a href="#">November 19, 2008</a>	None (earliest Version on record)

Version	A	B	Submitted Date	Changes
3	<input type="radio"/>	<input type="radio"/>	<a href="#">November 25, 2009</a>	Study Status, Contacts/Locations, Conditions and Sponsor/Collaborators
4	<input type="radio"/>	<input type="radio"/>	<a href="#">January 6, 2010</a>	Contacts/Locations and Study Status
5	<input type="radio"/>	<input type="radio"/>	<a href="#">July 19, 2010</a>	Contacts/Locations and Study Status
6	<input type="radio"/>	<input type="radio"/>	<a href="#">January 5, 2011</a>	Study Status
7	<input type="radio"/>	<input type="radio"/>	<a href="#">January 21, 2011</a>	Recruitment Status, Study Status and Contacts/Locations
8	<input type="radio"/>	<input type="radio"/>	<a href="#">February 11, 2011</a>	Study Status
9	<input type="radio"/>	<input type="radio"/>	<a href="#">February 16, 2011</a>	Study Design and Study Status
10	<input type="radio"/>	<input type="radio"/>	<a href="#">April 17, 2011</a>	Study Status
11	<input type="radio"/>	<input type="radio"/>	<a href="#">May 27, 2011</a>	Arms and Interventions and Study Status
12	<input type="radio"/>	<input type="radio"/>	<a href="#">January 6, 2012</a>	Recruitment Status, Study Status, Sponsor/Collaborators and Contacts/Locations
13	<input type="radio"/>	<input type="radio"/>	<a href="#">August 30, 2012</a>	Study Status ▶ Results Submission Events
14	<input type="radio"/>	<input type="radio"/>	<a href="#">November 13, 2020</a>	Recruitment Status, Study Status, Outcome Measures, Arms and Interventions, Mo Design, Study Description, Adverse Events, Baseline Characteristics, Participant Flo and Study Identification

Compare

Comparison Format:

Merged

Side-by-Side

[Scroll up to access the controls](#)

**Study NCT00794417**

**Submitted Date: November 19, 2008 (v1)**

▼ **Study Identification**

Unique Protocol ID: VGFT-ST-0708

Brief Title: A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Carcinoma

Official Title: A Phase 1/2 Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Carcinoma

Secondary IDs: TCD10767

▼ **Study Status**

Record Verification: November 2008

Overall Status: Recruiting

Study Start: September 2008

Primary Completion: September 2010 [Anticipated]

Study Completion: October 2010 [Anticipated]

First Submitted: November 19, 2008

First Submitted that Met QC Criteria: November 19, 2008

Met QC Criteria:

First Posted: November 20, 2008 [Estimate]

Last Update Submitted that Met QC Criteria: November 19, 2008

Met QC Criteria:

Last Update Posted: November 20, 2008 [Estimate]

▼ **Sponsor/Collaborators**

Sponsor: Regeneron Pharmaceuticals

Responsible Party:

Collaborators: Sanofi

▼ **Oversight**

U.S. FDA-regulated Drug:

U.S. FDA-regulated Device:

Data Monitoring: No

▼ **Study Description**

**Brief Summary:** The purpose of the study is to determine whether the combination of aflibercept, pemetrexed, and cisplatin is safe and effective.

**Detailed Description:** The study will be conducted in two phases. In phase 1, patients with advanced cancer will receive different doses of aflibercept in combination with approved doses of pemetrexed and cisplatin. The primary goal of phase 1 is to determine the safest dose of the combined study medications. This dose will then be administered to patients with previously untreated non-small cell lung cancer in phase 2. The primary goal of phase 2 is to determine if the combination is effective in treating non-small cell lung cancer. A portion of the study will determine if the combination is effective in treating non-small cell lung cancer.

▼ **Conditions**

Conditions: Advanced Carcinoma  
Non-Small Cell Lung Cancer

Keywords: advanced cancer  
lung cancer  
NSCLC  
Non-small Cell Lung Cancer  
afibercept  
chemotherapy

▼ **Study Design**

Study Type: Interventional

Primary Purpose: Treatment

Study Phase: Phase 1/Phase 2

Interventional Study Model: Single Group Assignment

Number of Arms: 1

Masking: None (Open Label)

Allocation: N/A

Enrollment: 100 [Anticipated]

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.